Business
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
TORONTO, February 24, 2026--Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.
About this update from Satellos Bioscience Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1301,"height":302,"url":"https://media.zenfs.com/en/business-wire.com/6177cb7f8b582217407f7092acee41dd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MTCRG__J6v6wxIjSYBiI_g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyMztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6177cb7f8b582217407f7092acee41dd","width":960,"height":223},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/CgEXLOduEberE8miXcv8jQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/6177cb7f8b582217407f7092acee41dd","width":1200,"height":279}},"lazy":false},{"type":"text","content":"TORONTO, February 24, 2026--(BUSINESS WIRE)--Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.","length":481,"tagName":"p"},{"type":"text","content":"Oral presentations feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (DMD), as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy (FSHD).","length":293,"tagName":"p"},{"type":"text","content":"Oral Presentations:","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Abstract Title: Assessing the impact of SAT-3247 on muscle force in a mouse model of FSHD","length":89,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Presenter: Phil Lambert, PhD, Satellos Chief Scientific Officer","length":63,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Time: Wednesday, Mar. 11, 9:30 – 9:45 a.m. ET","length":45,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Session: Novel Therapeutics Approaches","length":38,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Location: Florida 1-3","length":21,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulle...